

Full Name and Title	Dr Pinelopi Manousou, MD, PhD, FRCP
Email Address	<a href="mailto:Pinelopi.manousou@nhs.net">Pinelopi.manousou@nhs.net</a> <a href="mailto:p.manousou@imperial.ac.uk">p.manousou@imperial.ac.uk</a>
Title	Consultant in Hepatology and General Internal Medicine Honorary Associate Professor at the Institute of Liver and Digestive Health, Royal Free Hospital, UCL
Other appointments	Member of the Board of Directors, University of Ioannina, Greece; December 2022 – December 2026 National deputy specialty Lead for Hepatology, CRN NIHR Clinical Research Network Co-Lead for Hepatology in NW Thames, London BASL research development group member NW London CRN partnership EDI group member December 2022- December 2024 BRC Steering Committee member at Imperial BRC, January 2023 for 2 years Specialist Committee Member for NICE Diagnostics Advisory Committee– 2021- 2022: MRI-based technologies for assessing non-alcoholic fatty liver disease.
Higher Education:	2013-2015 EASL Sheila Sherlock post Doc fellowship, UCL, Royal Free Hospital 10/2012 University Hospital of Ioannina, Greece; CCT in Gastroenterology 7/2010 University of Crete, Greece; PhD 7/2001 University of Ioannina, Greece; MD
Membership of Professional Bodies	GMC special registry 2005 EASL member since 2012 Fellow of the Royal College of Physicians since 2018 AASLD member

### Appointments/Training

Title of Appointment	Dates	Department/Other Organisation	Brief Description of Responsibilities
Consultant in Hepatology and GIM	3/2015-today	St Mary's Hospital, Imperial College NHS Trust	I am currently Lead Hepatologist for our SLD services, including its clinical development, governance and associated clinical research.
Senior Clinical Fellow in Hepatology and EASL post Doc fellowship	11/2012-3/2015	Liver Transplant Unit, Royal Free Hospital	Liver Transplant and ICU training. EASL Sheila Sherlock post Doc fellowship holder 2013-2015 for a project entitled 'Continuous assessment of liver fibrosis progression ex vivo by studying cell to cell interaction'.
Senior Registrar Training Gastroenterology	6/2009-10/2012	Gastroenterology and Hepatology, University Hospital of Ioannina, Greece	Completion of training in Gastroenterology.
Senior Clinical Fellow Hepatology	10/2006-6/2009	Royal Free Hospital, London	Hepatology training and sub-PI in RCT about immunosuppression post LT
PhD student	1/2003-10/2006	Liver Unit, University of Crete	The role of chemokines and cytokines in epithelial and lymphocytic interactions in the mucosa of IBD patients
Core training (CT2) and ST training in Internal Medicine	09/2001-1/2003	Greek-Albanian borders and isolated Greek islands in the Aegean Sea	Full-time; training in GIM and cardiology in remote and difficult to access areas of the country

## **Current role**

I am a Consultant in Hepatology and General Internal Medicine. I am the Lead for our Steatotic Liver Disease service, including its clinical development, governance, and associated research. During the last years, I have expanded the clinical services with one more clinic per week, currently caring for 1100 patients, registered in our database and extensively phenotyped. I have also set up a weekly SLD MDT with endocrinologists, bariatric surgeons, pathologists, research nurses, dieticians, and obesity psychiatrists, discussing patients' care and management pathways. Furthermore, I have set up a weekly SLD research team meeting which brings together a wide spectrum of disciplines and represent the enormous benefits of collaboration with several publications, collaborative works and grant applications coming out of this group.

I have organised a patients and public Steatotic Liver Disease group (PPIE SLD group), with whom we meet monthly to discuss about patients' care and support and use their feedback and suggestions to shape our service. Our dedicated PPIE SLD group also participates in research study design and in the preparation of patient-facing materials.

I was recently appointed as a senior member of the board of Directors in University of Ioannina. This is a team of 11 academics with extensive responsibilities, including the strategic plan of the University and its mission in academic and research policy, lifelong learning, and education, strengthening the Foundation's extroversion and internationalization, strengthening the connection with society and the economy, development of innovation and upgrading the quality of the academic environment. Another responsibility is the design and implementation of the detailed annual budget of university. This is an exciting role and honour as University of Ioannina hosts 30,000 undergraduate students, 4800 postgraduate students and 690 faculty members. It is organized in 11 Schools, 23 Undergraduate Courses of Study and 33 Postgraduate Study Programmes. According to the 2017 Leiden rankings the University of Ioannina is ranked #2 overall in Greece. The Faculty of Medicine of the University of Ioannina is ranked 1<sup>st</sup> among all Medical Faculties in Greek Tertiary Education.

As the Deputy National Specialty Lead NIHR, I am providing leadership for specialty focused health and social care research at national level, promoting engagement and subsequent delivery of specialty research studies. In conjunction with the Medical Director, Cluster Leads, National Specialty Leads, and local network Clinical Directors, I am an ambassador for the NIHR CRN.

As a CRN co-lead for Hepatology, I am managing a busy team of CRN nurses, technicians and PIs and I am holding meetings once weekly to ensure that our services are performing on high capacity. I have recently been awarded two CHT Division of Medicine & Integrated Care Funding Award, (for appointing a sub-PI) and two NIHR CRN post-COVID Managed Recovery Funding for supporting our Clinical Research activities. With a dedicated clinical research team, I am running 10 International Commercial studies as a PI and 2 as a CI.

Since 2012, I am leading a group of Image Analysis Experts and Application Developers (European Regional Development Fund - ERDF 'Collagen morphometric analysis in liver biopsies), whom with we have managed to develop and install the quantitation of liver biopsy images, and now working on Deep Learning Image Analysis. Through improved diagnosis and earlier treatment strategies, this work has the potential to make a substantial impact on the morbidity and mortality of this patient group.

Last, but not least, I am proud of setting up a European consortium for exploring the prevalence of steatotic liver disease in patients with chronic hepatitis B, across 27 centres in Europe.

We are also participating in two Horizon Consortiums, the ARTEMIs Project led by Toulouse University and Leonardo (HORIZON-HLTH-2024-STAYHLTH-01-05): Personalised prevention of non-communicable diseases program" led by University of Milan.

I am active in teaching and lecturing and I currently supervise 4 PhD students and 7 BSC students, who have all published their work or is under review. We have been granted and co-organised an EASL basic school of Hepatology this year with Julian Marchesi, Benjamin Mullish, Debbie Shawcross, Mark Thursz and Palak Trivedi. The school focused on the contribution of gut-liver axis to a range of chronic liver diseases, the growing pertinence of antimicrobial resistance to cirrhosis, and the manipulation of the gut microbiome as a novel approach to treatment.

### **Management/ Leadership**

My managerial and leadership experience is demonstrated by my current appointments:

1. Member of the Board of Directors, University of Ioannina, Greece; December 2022 – December 2026
2. Deputy National Specialty Lead for Clinical Research Network, NIHR, UK
3. Clinical Research Network Co-Lead for Hepatology in NW Thames, London for the last 4 years
4. MASLD group leader at Imperial
5. EASL basic school of Hepatology co-organiser: Microbiome in chronic liver disease (Sept 2023)
6. BRC Steering Committee member at Imperial BRC, January 2023 for 2 years
7. BASL research development group member
8. NW London CRN partnership EDI group member 2022- 2024
9. Specialist Committee Member for NICE Diagnostics Advisory Committee– 2021- 2022: MRI-based technologies for assessing non-alcoholic fatty liver disease.

### **Research Interests**

1. Development of a European registry across 27 centers in 7 countries for patients with Chronic Hepatitis B and SLD, exploring the prevalence of steatotic liver disease in people with CHB
2. Another major interest of our group is a risk-stratification and economic analysis for the development of a SLD referral/management strategy pathway in the diabetic population in three different healthcare systems: the UK, Sicily and Egypt.
3. Another major interest of our group is applying artificial intelligence in the interpretation of liver biopsies. The software we are developing is based on a deep-learning approach which means that it is designed to refine its knowledge and become more accurate automatically as it is used.
4. Open label single centre phase 2 trial of Faecal Microbial Transplantation in patients with Metabolic-Associated Steatotic Liver Disease and advanced fibrosis in collaboration with [Professor Mark Thursz](#), [Professor Marc Dumas](#) and [Dr Benjamin Mullish](#).
5. Building an integrated care model to tackle multimorbidity in people with mental health conditions: screening strategy and community-based management pathway for liver fibrosis and metabolic risk factors.

### **Other projects currently leading or co-leading**

1. The role of microbiome and gut permeability in modulating sarcopenia in diabetic patients with Non-alcoholic fatty liver disease: a cross-sectional multicentre study (Milan).

2. An open-label randomized control trial for diabetic patients with SLD comparing dietary advice and feedback informed by metabolic profiling to standard of care aiming to improve dietary habits during a 12-week period in collaboration with [Professor Gary Frost](#).
3. Developing the glucagon-alanine index test to improve the health of people with non- alcoholic fatty liver disease by [Professor Tricia Tan](#)
4. Identification of NASH contributing factors with single-cell omics by [Dr Ines Cebola](#)
5. Discovery of SLD gene regulatory networks, The Wellcome Trust, Sir Henry Dale Fellowship by [Dr Ines Cebola](#)

**Contributions To Education**

1. Book Chapter: Liver Biopsy  
B H. Mullish, N Kumar, R D. Goldin, P Manousou  
Evidence-based Gastroenterology and Hepatology, Fourth Edition  
Editors: Brian G Feagan, Peter J Kahrilas, Rajiv Jalan, John W D McDonald
2. Invited teaching lectures both nationally (Royal Free Liver Postgraduate course) and internationally (Hellenic Society of Hepatology; European Young Hepatologists Workshop, UEGW, EASL SLD summit)
3. Co-organiser of the EASL Basic School of Hepatology on “Microbiome in Chronic Liver Disease” in 2023
4. External reviewer for the MRC, NIHR, the PSI foundation Grant, over the last two years, the RoseTrees Trust Grant, the Swiss National Science Foundation.

Degree	Start Date	End Date	Student	Title of Project
PhD	02/2020	Writing up	Dan Wang	Defining the Lipidome of MASH
PhD	11/2020	LSA Nov 2023	Jian Huang	Lipid metabolism in MAFLD-associated HCC
PhD	03/2023	ESA Nov 2023	Anastasia Constantinou	Precision nutrition for non-communicable disease
PhD	10/2023	started	Dimitrios Patseas	Immune (dys)regulation mediated by immunecheckpoint pathways in chronic liver disease.
PhD	11/2019	Writing up	Nadeen Habboub	Investigating the Impact of Faecal Microbiota Transplant on the Metabolome and Clinical Phenome of Patients with MASLD
PhD	5/2018	Completed	Roberta Forlano	Prevalence of Liver Disease in patients with Type 2 Diabetes Mellitus. Screening policy, ec cost analysis
Bsc	2023	Completed	Madeleine Lacey	Role of MASLD in modifying clinical outcomes in Chronic Hepatitis B (CHB): a multicentre, prospective cohort study.
Bsc	2023	Completed	Thishana Kirupakaran	Exploring the quality of life and perception around diet in a cohort of patients with MASLD
Bsc	2023	Completed	Efstratios Chatzieleftheriou	Assessing liver biopsies in MASLD by a deep learning based quantitative technique.
Bsc	2023	Completed	Margaux Couffon	Prevalence and effect of sarcopenia in patients with MASLD/MASH
Bsc	2023	Completed	Maryam Shapoor	Exploring the effect of FMT in patients with MASH
Bsc	2023	Completed	Huma Malik	The effect of GLP-1 receptor agonists in patients with NASH.